Clin2Atlas
AtlasOther conditionsUrinary diseases and male infertility

Urinary tract infections and interstitial nephritis

4Curable or preventable in mostAI-generated

Urinary tract infections are curable, but resistance is a growing concern.AI-generated

Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251989 — Cefixime approved (FDA)1990 — Fluconazole approved (FDA)1993 — Tazobactam approved (FDA)1996 — Meropenem approved (FDA)1996 — Cefepime approved (FDA)1996 — Levofloxacin anhydrous approved (FDA)1996 — Fosfomycin approved (FDA)2007 — Doripenem approved (FDA)2011 — Methylene blue cation approved (FDA)2014 — Ceftolozane approved (FDA)2015 — Avibactam approved (FDA)2017 — Vaborbactam approved (FDA)2018 — Plazomicin approved (FDA)2019 — Cefiderocol approved (FDA)2019 — Relebactam anhydrous approved (FDA)2024 — Amdinocillin pivoxil approved (FDA)
1989: Drug approval — Cefixime approved (FDA). 1990: Drug approval — Fluconazole approved (FDA). 1993: Drug approval — Tazobactam approved (FDA). 1996: Drug approval — Meropenem approved (FDA). 1996: Drug approval — Cefepime approved (FDA). 1996: Drug approval — Levofloxacin anhydrous approved (FDA). 1996: Drug approval — Fosfomycin approved (FDA). 2007: Drug approval — Doripenem approved (FDA). 2011: Drug approval — Methylene blue cation approved (FDA). 2014: Drug approval — Ceftolozane approved (FDA). 2015: Drug approval — Avibactam approved (FDA). 2017: Drug approval — Vaborbactam approved (FDA). 2018: Drug approval — Plazomicin approved (FDA). 2019: Drug approval — Cefiderocol approved (FDA). 2019: Drug approval — Relebactam anhydrous approved (FDA). 2024: Drug approval — Amdinocillin pivoxil approved (FDA)

What's being tested now

2016: 1 trials started2018: 1 trials started2019: 3 trials started2020: 6 trials started2021: 3 trials started2022: 9 trials started2023: 13 trials started2024: 21 trials started2025: 29 trials started2026: 37 trials started2020202637

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 119 active Pyelonephritis trials on Clin2 →

Where we are

AI-generated

Urinary tract infections are curable or preventable in most patients with short antibiotic courses. Most interstitial nephritis improves when the trigger is removed. Deaths are uncommon, but antibiotic resistance is gradually making some infections harder to treat. The approval of nitrofurantoin in 1953 gave medicine a safe, effective option that remains widely used. Since then, the main challenge has been preserving that effectiveness.

Can a urinary tract infection be completely cured?
In most cases, yes. A short course of antibiotics clears the infection. Some infections are harder to treat if bacteria are resistant, but other antibiotic options usually remain.
What is interstitial nephritis and is it reversible?
It is inflammation of the kidney tissue, often caused by certain medications or infections. If the trigger is stopped early, many people recover fully. Advanced or chronic cases can lead to permanent kidney damage.
How fast are new treatments being developed?
More than 100 trials have started in the past five years, including several late-stage studies. Research focuses on new antibiotics and ways to prevent infections, especially against resistant bacteria.
Why are antibiotic-resistant urinary tract infections a concern?
Resistance means some standard drugs stop working. This can make infections last longer and require stronger or intravenous antibiotics. Doctors track resistance patterns to choose effective treatments.
Are there ways to prevent urinary tract infections?
Yes, several approaches help, such as drinking enough fluids, urinating after activity, and certain hygiene habits. Some preventive antibiotics are used in frequent cases, though they are not for everyone.

Related

UrolithiasisBenign prostatic hyperplasiaMale infertilityOther urinary diseases

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.